State of Wyoming Invests $583,000 in BioCryst Pharmaceuticals, Inc. $BCRX

State of Wyoming purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 58,264 shares of the biotechnology company’s stock, valued at approximately $583,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Larson Financial Group LLC lifted its stake in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $81,000. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BCRX. Royal Bank Of Canada dropped their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Citizens Jmp raised their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $9.74 on Monday. The company has a 50 day moving average of $9.50 and a two-hundred day moving average of $8.84. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -6.49 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.15 earnings per share. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.